NL-OMON35086已完成不适用
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE DOSES OF 2-IMINOBIOTINE (2-IB) IN HEALTHY MALE SUBJECTS - First-in-human 2-IB dose escalation study
europhyxia B.V.0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male, 18-55 years of age, BMI 18 and 28 kg/m2, total body weight does not exceed 90 kg, a good venous accessibility for both arms, non or moderate smoker
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
进行中（未招募）
1 期
A study, with chance selection of treatment unknown to the patients and doctors, to test theUlaritide as treatment for Acute Kidney Ingury in patients post cardiac surgeryAcute kidney injury in patients post cardiac surgeryMedDRA version: 21.1Level: PTClassification code 10069339Term: Acute kidney injurySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2018-004871-11-DECardiorentis AG45
进行中（未招募）
不适用
RANDOMIZED DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO-CONTROLLED STUDY TO DETERMINE THE INSULIN SENSITIZING EFFECT OF BGP-15 IN PATIENTS WITH INSULIN RESISTANCE - THE INSULIN SENSITIZING EFFECT OF BGP-15EUCTR2005-000872-41-HU-Gene Research & Development Ltd.
进行中（未招募）
1 期
STUDY OF EFFECTIVENESS, TOLERABILITY AND SAFETY OF THERAPY WITH AMANTADINE IN DEGENERATIVE ATAXIASDegenerative ataxiasEUCTR2012-003315-63-ESFIBHULP150
进行中（未招募）
1 期
A study to determine the efficacy and safety of fasinumab for the treatment of adults with lower back paiChronic Low Back PainMedDRA version: 19.0Level: PTClassification code 10003988Term: Back painSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-003782-28-PLRegeneron Pharmaceuticals, Inc.800
进行中（未招募）
1 期
A study to determine the efficacy and safety of fasinumab for the treatment of adults with lower back paiChronic Low Back PainMedDRA version: 20.0Level: PTClassification code 10003988Term: Back painSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-003782-28-CZRegeneron Pharmaceuticals, Inc.800